tRFVal-AAC-035 is used to detect diabetic cardiomyopathy.

By detecting and regulating the tRFVal-AAC-035 small RNA molecule, the problem of regulating the mode of cardiomyocyte death in diabetic cardiomyopathy was solved, achieving the effect of reversing the disease process and improving cardiac function.

CN116004617BActive Publication Date: 2026-11-17THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210913561.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-01
Publication Date
2026-11-17
Estimated Expiration
2042-08-01

AI Technical Summary

Technical Problem

Currently, there are no effective means to regulate the way cardiomyocytes die in diabetic cardiomyopathy, which leads to aggravated cardiac function damage, and existing technologies cannot reverse the disease process.

Method used

Using tRFVal-AAC-035 small RNA molecules as markers, we detected its expression levels in serum and myocardial tissues, and performed quantitative analysis using real-time PCR technology. The assay kit was used to detect the regulation of the expression of target genes such as CAMKK2, PI3K, and IKK, thereby regulating autophagy, pyroptosis, and ferroptosis in cardiomyocytes.

Benefits of technology

By regulating cell death pathways, tRFVal-AAC-035 can alleviate cardiomyocyte damage, improve cardiac function, and reverse the course of diabetic cardiomyopathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116004617B_ABST
    Figure CN116004617B_ABST
Patent Text Reader

Abstract

This invention relates to the application of a small tRNA-derived RNA, tRFVal-AAC-035, in the diagnosis of diabetic cardiomyopathy. The structure of tRFVal-AAC-035 is as follows: GTTTCCGTAGTGTAGTGGTCATCA. tRFVal-AAC-035 is a small tRNA-derived RNA screened by the inventors through sequencing. This invention provides the application of tRFVal-AAC-035 as a marker in the diagnosis and treatment of diabetic cardiomyopathy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the application of a small RNA derived from tRNA in the diagnosis of diseases, and particularly to the use of tRFVal-AAC-035 to detect diabetic cardiomyopathy. Background Technology

[0002] (1) Analysis of the relationship between myocardial cell death mode and the progression of diabetic cardiomyopathy

[0003] Studies have shown that in diabetes, metabolic changes such as pancreatic β-cell dysfunction, hyperglycemia, and elevated free fatty acid levels lead to mitochondrial dysfunction, increased inflammation, and the formation of advanced glycation end products (AGEs), ultimately causing cardiomyocyte death and myocardial fibrosis. As permanent cells, cardiomyocytes have extremely weak regenerative capacity; their mass death directly impairs cardiac function, thus accelerating the progression of diabetic muscular dystrophy (DCM). Early research on cardiomyocyte death in DCM mainly focused on apoptosis and necrosis. However, with the deepening of research in this field, autophagy, pyroptosis, and ferroptosis have gradually become hot research topics due to their physiological relevance to DCM.

[0004] (2) Research on the role of tRF in complex diseases

[0005] Currently, it is widely believed in the industry that ncRNAs play an important regulatory role in various diseases such as heart failure and diabetes. Two previously completed National Natural Science Foundation of China projects from our research group, "A Novel Mechanism of Circular RNA (circ_0076631) Targeting miR-214 / 133 to Regulate Diabetic Cardiomyopathy" and "The Therapeutic Effect of Multi-Target MicroRNA Intervention Technology on Regulating the GLUT4 Signaling Pathway in Diabetes," both demonstrate the important role of ncRNAs in diabetic cardiomyopathy (DCM). In summary, our research group found that inhibiting miR-150-5p can alleviate myocardial inflammation and fibrosis in DCM. Furthermore, lncRNA-KCNQ1OT1 and circRNA-CACR exert their effects by regulating pyroptosis in DCM. These findings suggest that ncRNAs may play an important role in DCM by regulating cell death. As one of the most researched areas in the field of ncRNAs in recent years, related studies both domestically and internationally have confirmed the abnormal expression of tRF in various complex diseases. In cardiovascular diseases, metabolic disorders, oxidative stress, and aging are the main causes of abnormal tRF expression and potential targets for improving myocardial ischemia injury through caloric restriction pretreatment.

[0006] Studies on tRF and cell death have found that tRF-3001b can exacerbate the development of non-alcoholic fatty liver disease by inhibiting autophagy, tRF3-Thr-AGT can alleviate the progression of acute pancreatitis by inhibiting ZBP1 / NLRP3-mediated pyroptosis, and phosphoserine-tRNA kinase has been shown to be associated with inhibiting chemotherapy-induced ferroptosis in hepatocellular carcinoma cells. Furthermore, researchers found that in colorectal cancer, the expression of two tRFs (tRF-phe-GAA-031 and tRF-VAL-TCA-002) was significantly upregulated and closely related to clinical stage. Similarly, in the serum of gastric cancer patients, the expression level of tRF (hsa_tsr016141) showed a gradient among gastric cancer patients, gastritis patients, and healthy controls, and was positively correlated with the degree of lymph node metastasis and tumor grade, confirming the time specificity of tRF in the disease. Furthermore, studies have shown that at the tRNA level, disease-related expression changes primarily occur in tRFs rather than mature tRNAs, and these changes are cell- and tissue-specific. These studies demonstrate that tRF expression is spatiotemporally specific and possesses the ability to dynamically regulate multiple pathways, making it an ideal molecular type for studying DCM. However, the role of tRFs in DCM and their association with cardiomyocyte death pathways remain unknown. Based on previous research, we believe that tRFs may play a dynamic and crucial regulatory role in the occurrence and development of DCM by dynamically regulating multiple signaling pathways and thus influencing cell death pathways.

[0007] (3) Regulating autophagy, pyroptosis, and ferroptosis in cardiomyocytes is a core issue in successfully reversing diabetic cardiomyopathy. Diabetic cardiomyopathy (DCM) is a serious disease with insidious onset and high mortality, and there are currently no effective treatments. The microscopic feature most strongly correlated with clinical manifestations in its development is cardiomyocyte death, which includes apoptosis, pyroptosis, autophagy, and ferroptosis (see our group's review published in Acta Pharmaceutica Sinica B in 2022 (IF=11.614)). In diabetic cardiomyopathy, cardiomyocyte apoptosis mainly occurs in the late stage of the disease, making it suitable for determining the disease progression. Autophagy, pyroptosis, and ferroptosis occur throughout the entire disease process, and therefore, regulating them can reverse diabetic cardiomyopathy. Our previous research has also confirmed that appropriately activating autophagy and inhibiting pyroptosis and ferroptosis can reduce cardiomyocyte damage, thereby improving adverse cardiac remodeling induced by diabetic cardiomyopathy and alleviating cardiac function.

[0008] (4) tRFVal-AAC-035 is a key molecule regulating cardiomyocyte death and reversing disease progression. Small RNAs derived from tRNA (tRNA-derived fragments, tRFs) have unique properties that regulate changes in DNA, RNA, and protein expression. They can exert post-transcriptional regulatory effects as non-coding RNA (ncRNA) and also function at the protein translation level, making them novel molecules with comprehensive regulatory effects on cellular state changes. More importantly, tRFs can regulate cell death, but their role in diabetic cardiomyopathy is unknown. Our preliminary experiments have, for the first time, confirmed the role of tRF in diabetic cardiomyopathy. Specifically, a significantly downexpressed tRF (named tRFVal-AAC-035) was detected in the serum of diabetic cardiomyopathy patients, myocardial tissue of diabetic mice, and high-glucose-treated cardiomyocytes. Its downstream target genes, CAMKK2, IKK, and PI3K, also showed abnormal expression, leading to weakened myocardial autophagy, activated pyroptosis, and increased ferroptosis. Overexpression of tRFVal-AAC-035 could regulate these three cell death pathways, thereby alleviating cardiac dysfunction. These preliminary results confirm that tRFVal-AAC-035 is a key molecule in regulating cardiomyocyte death and reversing disease progression. However, its specific molecular mechanism still needs further elucidation, and its correlation with changes in clinical symptoms and disease progression requires systematic analysis and verification. Summary of the Invention:

[0009] This invention provides an RNA molecule named tRFVal-AAC-035.

[0010] Its structure is as follows: GTTTCCGTAGTGTAGTGGTCATCA

[0011] tRFVal-AAC-035 is a small RNA derived from tRNA that was screened by the inventors through sequencing. There are currently no reports on it in the literature.

[0012] The present invention further provides the application of tRFVal-AAC-035 as a marker in the diagnosis and treatment of diabetic cardiomyopathy.

[0013] The preparation method of tRFVal-AAC-035 is as follows:

[0014] tRFVal-AAC-035 is a small RNA derived from tRNA, belonging to non-coding RNA. Its extraction follows standard RNA extraction procedures. RNA extraction: RNA was extracted from heart tissue and cardiomyocytes using the Trizol method. To prevent RNA degradation, all procedures were performed on ice. After adding 1 mL of Trizol to each sample, the surface of the culture plate was scraped with a clean cell scraper to ensure complete lysis of the cardiomyocytes in the Trizol solution. The Trizol lysate was then collected into EP tubes. The RNA extraction procedure was the same after collection. The Trizol solution was incubated in the EP tubes for 2 minutes to ensure complete lysis of the tissues and cells. 0.2 mL of chloroform was added to each EP tube, and the solution was vortexed to mix thoroughly. The tubes were then incubated for 10 minutes. After incubation, the tubes were centrifuged at 13,500 rpm for 15 minutes at 4°C. At this point, the EP tube shows clearly visible layers: a colorless, transparent liquid at the top (where the RNA is retained), a thin white layer in the middle (containing proteins and DNA), and a pink, transparent liquid at the bottom (an organic phase containing chloroform). Carefully aspirate the supernatant into a new EP tube, being careful to only aspirate 0.4 mL to avoid contaminating the RNA with impurities from other layers. After aspirating, add 0.5 mL of isopropanol solution, gently invert the EP tube manually to mix the solution, and let it stand for 10 minutes. After standing, centrifuge at 13500 rpm for 10 minutes at 4°C. After centrifugation, a small white, feathery RNA precipitate will be visible at the bottom of the EP tube. Discard the liquid in the tube and add 1 mL of 75% DEPC ethanol solution (prepared in advance with anhydrous ethanol and DEPC at a 3:1 ratio, and pre-chilled on ice). Gently invert the EP tube to resuspend the RNA precipitate at the bottom. Centrifuge at 10600 rpm for 5 minutes at 4°C. Discard the liquid in the tube after centrifugation and wipe the liquid off the EP tube wall with filter paper. Add 10 μL of DEPC solution to dissolve the RNA. RNA concentration determination: To determine the integrity of the extracted total RNA, agarose gel electrophoresis is required. If the 18S, 28S, and 5S bands are clearly visible in the electrophoresis pattern, and the 28S band is twice as bright as the 18S band, it indicates that the extracted RNA is intact and undegraded, and can be used for subsequent experiments. Use Nanodrop to detect the RNA concentration and dilute it to a stable range to reduce experimental errors in subsequent operations. Reverse transcription: Prepare the reaction system according to the Taqman MicroRNA Assays instructions. The total volume is 20 μL: 4 μL Allmix, 1 μL Remover, 0.5 μg RNA, and make up the remaining volume with ddH2O. The sample should be added on ice. Reaction procedure: 42℃ for 15 minutes, 85℃ for 15 seconds. After the reaction is complete, wait for the temperature to drop to 4℃, then store at -20℃ for later use.

[0015] The detection method for tRFVal-AAC-035 is as follows:

[0016] Real-time PCR: Using cDNA obtained after reverse transcription as a template, the target gene is amplified. Add the reaction mixture prepared according to Table 3 to a 96-well plate suitable for PCR, then add 1 μL of sample. Cover the 96-well plate with a membrane and centrifuge at 1000 rpm for 1 minute. Set the PCR amplification conditions according to Table 4.

[0017] qRT-PCR reaction system

[0018]

[0019] qRT-PCR reaction program

[0020]

[0021] The present invention further provides a method for detecting the content of tRFVal-AAC-035.

[0022] This invention uses a fluorescence PCR quantitative method to detect the content of tRFVal-AAC-035, as exemplified below:

[0023] Total RNA was extracted from left ventricular tissue and primary cardiomyocytes. The concentration and purity of the RNA samples were determined using a nanodrop spectrophotometer. A reverse transcription system was prepared according to the determined concentration and a Toyobo reverse transcription kit. After mixing and centrifugation, the samples were reverse transcribed into cDNA. The PCR reaction mixture was added to 96-well plates, and the cDNA was amplified and detected using a real-time PCR system. U6 and actin were used as internal controls, and 2... -△△Ct The expression level of RNA was calculated using this method.

[0024] The present invention further provides a kit for detecting the content of tRFVal-AAC-035.

[0025] The kit includes any reagent that can be used to detect the tRFVal-AAC-035 content, such as a solvent or solute, selected from organic solvents, inorganic solvents, buffer solutions, water, etc. The kit may also include instructions, reagent bottles, reagent packs, swabs, droppers, and other auxiliary devices. The reagents in the kit can be used to test one person or multiple people, such as 5, 10, 20, 50, or 100 people. The test should be performed according to the instructions.

[0026] This invention further provides structural confirmation of the tRFVal-AAC-035 molecule:

[0027] The primary structure of tRFVal-AAC-035 was obtained through RNA sequencing. This invention used Arraystar tRF & tiRNA technology to sequence the heart tissue of diabetic fibrosis (DCM) mice, and validated the results at the cellular and clinical levels. The tRF with the most significant expression changes (decreases) in DCM was screened as a candidate for analysis and named tRFVal-AAC-035. Based on this, cellular experiments revealed decreased LC3-II and p62 expression in CMs treated with high glucose; however, upregulation of tRFVal-AAC-035 led to increased autophagy and decreased proliferation, suggesting that reduced tRFVal-AAC-035 expression in diabetic patients may lead to reduced autophagy, exacerbating diabetic myocardial fibrosis and thus contributing to the development of DCM. This confirms that tRFVal-AAC-035 participates in the regulation of autophagy.

[0028] The inventors further investigated the roles of tRFVal-AAC-035 target genes CAMKK2, PI3K, and IKK in diabetes mellitus. The results showed that tRFVal-AAC-035 target genes are widely involved in pathways related to autophagy, pyroptosis, and ferroptosis. Through dual-luciferase reporter gene assays, CAMKK2, PI3K, and IKK were identified as representative downstream target genes and experimentally verified. The results showed that tRFVal-AAC-035 can regulate the expression of these genes; CAMKK2 and PI3K expression was significantly decreased in diabetic cerebral palsy (DCM), while IKK expression was increased.

[0029] Furthermore, studies on CAMKK2 have revealed that upon activation by Ca2+ in cardiomyocytes, this gene specifically regulates AMPK, affecting autophagy and ferroptosis in cardiomyocytes, thereby regulating cardiac injury. Moreover, CAMKK2 participates in autophagy and ferroptosis pathways, while AMPK is a node in these pathways; therefore, the two may be key points of interaction in signaling pathways. For example, the histone demethylase JMJD1C affects the occurrence and development of myocardial hypertrophy by regulating the CAMKK2 / AMPK signaling pathway.28 Further, CAMKK2 has been shown to regulate diabetic cerebral palsy (DCM). Specifically, after tetrahydrofolate interacts with CAMKK2, it activates the CREB / AMPK / PGC-1α signaling pathway, thereby affecting mitochondrial function in cardiomyocytes during DCM.29 Furthermore, CAMKK2 is significantly activated in ferroptosis, negatively regulating ferroptosis by activating NRF2 and inhibiting lipid peroxidation.30 The study also found that NCAPD2 activates intracellular Ca2+ in cardiomyocytes and then inhibits autophagy through the CAMKK2 / AMPK / mTORC1 signaling pathway.

[0030] In summary, the study shows that tRFVal-AAC-035 expression is significantly reduced in DCM, inhibits CAMKK2 expression, exacerbates ferroptosis, reduces autophagy, and worsens diabetic cardiac dysfunction.

[0031] Unlike CAMKK2, the mechanisms by which IKK and PI3K participate in the regulation of diabetic cardiomyopathy (DCM) by tRFVal-AAC-035 remain unclear. Related studies have shown that in a hyperglycemic environment, the IKK complex is phosphorylated and subsequently ubiquitinated via the polyol bypass pathway, advanced glycation end products (AGEs) pathway, and oxidative stress pathway. This leads to further degradation by proteases, releasing NF-κB from the complex and translocating it to the nucleus. This, in turn, significantly increases NF-κB expression in diabetic cardiomyocytes, ultimately contributing to the occurrence and development of DCM through inflammatory responses. Furthermore, research has found that activating the PI3K signaling pathway can inhibit NF-κB expression, reduce inflammation, increase insulin sensitivity, and ultimately suppress hyperglycemic damage to cardiomyocytes. In the above process, the inflammatory response is a characteristic of IKK and PI3K, and pyroptosis, also known as inflammatory necrosis, is characterized by the induction of an inflammatory response. This suggests that tRFVal-AAC-035 may regulate pyroptosis and autophagy by influencing pathways such as NF-κB through IKK and PI3K. Attached Figure Description

[0032] Figure 1 High-fat diet + STZ-induced diabetic myocardial injury and increased ferroptosis in high-glucose cardiomyocytes were observed in mice. A. Ultrasound analysis of cardiac function in mice; B. HE staining analysis of cardiac morphology; C. TUNEL staining analysis of cardiomyocyte death; D, E. Western blotting analysis of protein expression in cardiac tissue and cardiomyocytes. *P<0.05 vssham / Crtl.n=3-20.

[0033] Figure 2 Detection of tRFVal-AAC-035 expression in diabetic-induced myocardial injury. A. Arraystar tRF & tiRNA gene chip technology was used to screen differentially expressed tRFs in the myocardial tissues of normal mice and type 2 diabetic mice; B. PCR technology was used to verify differentially expressed tRFs in high glucose + PA-induced cardiomyocytes; C, D, E, F. PCR technology was used to detect tRFVal-AAC-035 expression in cardiomyocytes, diabetic heart tissues, human AC16 cells, and serum of diabetic patients, respectively. *P<0.05 vs sham / Control.n=6-17.

[0034] Figure 3tRFVal-AAC-035 inhibited the reduction in autophagy in cardiomyocytes induced by high glucose + PA. A, B. Western blotting was used to detect the expression of related proteins in cardiac tissue and cardiomyocytes of diabetic cardiomyopathy. *P<0.05 vs sham / Ctrl.n=4-7; C, D. Western blotting was used to detect the expression of autophagy-related proteins in cardiomyocytes induced by high glucose. *P<0.05 vs Mimic-NC+HG / Inhibitor-NC+HG.n=3-4.

[0035] Figure 4 Bioinformatics prediction of downstream target genes CAMKK2, PI3K, and IKK of tRFVal-AAC-035: Using the tRFVal-AAC-035 sequence (GTTTCCGTAGTGTAGTGGTCATCA) as input and human whole-genome sequence data as background, candidate target genes were predicted using TargetScan and miRanda algorithms. TargetScan yielded 920 candidate genes, and miRanda yielded 1256 candidate genes; the intersection of the two algorithms resulted in a candidate gene set of 783 genes.

[0036] Figure 5 CAMKK2 is mainly enriched in functional nodes and pathways related to ferroptosis (AMPK signaling pathway, GAD-IMMUNE), autophagy (MAPK cascade, calcium binding, calcium-dependent protein kinase activity, calcium ion binding, calcium-mediated signaling, ATP binding), and insulin resistance (Adipocytokine signaling pathway).

[0037] Figure 6 To verify the effects of high glucose + PA treatment and tRFVal-AAC-035 on the expression of CAMKK2, PI3K, and IKK. A, B. Western blotting and immunofluorescence techniques were used to detect the expression of CAMKK2, PI3K, and IKK in high glucose-induced cardiomyocytes; C. Western blotting was used to detect the expression of CAMKK2, PI3K, and IKK in cardiac tissue of diabetic cardiomyopathy. D, E. Transfection with Mimic-tRF-035 / Inhibitor-tRF-035 was used to detect the expression of CAMKK2, PI3K, and IKK. *#P<0.05 vs sham / Ctrol.n=3-10.

[0038] Figure 7tRFVal-AAC-035 inhibited the increased ferroptosis in cardiomyocytes induced by high glucose + PA. Western blotting (WB) and immunofluorescence (IFF) were used to detect the effect of tRFVal-AAC-035 on the expression of CAMKK2 in cardiomyocytes induced by high glucose + PA. Western blotting (WB) was used to detect the expression of ferroptosis-related proteins in cardiomyocytes induced by high glucose. *P<0.05 vs Mimic-NC+HG / Inhibitor-NC+HG. n=3-4. Detailed Implementation

[0039] The present invention will be further illustrated by the following examples.

[0040] Example 1

[0041] Increased ferroptosis in diabetic cardiomyopathy and high glucose-induced cardiomyocyte injury

[0042] A high-fat diet plus STZ-induced diabetic cardiomyopathy model was used in mice. After 12 weeks of modeling, compared with the control group, mice showed decreased cardiac function, increased heart volume, and increased number of dead cardiomyocytes. Simultaneous detection of ferroptosis-related proteins revealed increased ferroptosis in diabetic cardiomyopathy. In primary cardiomyocytes treated with high glucose plus PA, the expression of ferroptosis-related proteins, GPX4 and FTH1, was increased. (See...) Figure 1 .

[0043] Example 2: Screening and validating the expression of tRFs in diabetes-induced myocardial injury

[0044] In cardiac tissues of mice with high-fat + STZ-induced diabetic cardiomyopathy, Arraystar tRF & tiRNA gene chip sequencing was used to obtain multiple differentially expressed tRFs. The differentially expressed tRFs were validated in high-glucose + PA-induced cardiomyocytes, revealing that tRFVal-AAC-035 was the most significantly reduced. Simultaneously, tRFVal-AAC-035 expression was reduced in cardiomyocytes and AC16 cells treated with different concentrations of high glucose, in cardiac tissues of diabetic cardiomyopathy mice, and in serum of diabetic cardiomyopathy patients. See [link to relevant documentation]. Figure 2 .

[0045] Example 3: tRFVal-AAC-035 inhibits the reduction in autophagy induced by high glucose + PA in cardiomyocytes.

[0046] Primary cardiomyocytes treated with high glucose plus PA showed decreased expression of autophagy-related proteins, including LC3II / I and p62, indicating reduced autophagy. However, overexpression of tRFVal-AAC-035 inhibited this effect, while silencing tRFVal-AAC-035 exacerbated the reduction in autophagy induced by high glucose plus PA treatment. See [link to relevant documentation]. Figure 3 .

[0047] Example 4: Bioinformatics Prediction of Downstream Target Genes CAMKK2, PI3K, and IKK of tRFVal-AAC-035. Using the sequence of tRFVal-AAC-035 (GTTTCCGTAGTGTAGTGGTCATCA) as input and human whole-genome sequence data as background, candidate target genes were predicted using TargetScan and miRanda algorithms. TargetScan yielded 920 candidate genes, and miRanda yielded 1256 candidate genes. The intersection of the two algorithms resulted in a candidate gene set of 783 genes (e.g., ...). Figure 4 (As shown). Based on this, using the Gene Ontology, KEGG, and GAD databases, the DAVID EASE score is used to convert information from genes to biological pathways. Specifically, using the aforementioned candidate gene set li and the list of genes wa related to any functional node or pathway as input, the corrected Fisher exact p-value, i.e., EASE, is calculated. The specific calculation formula is as follows:

[0048]

[0049] The calculation methods for GH (gene hit rate), GT (total number of genes), OH (genome hit rate), and OT (total number of genomes) are shown in the table below:

[0050]

[0051] A value of e not exceeding the threshold supports another hypothesis: the probability of the first cell in the 2x2 table is actually greater than the expected probability under the null hypothesis that the two variables are independent. The conclusion is that there is a correlation between the row and column variables in the table, meaning that the proportion of genes belonging to each category differs between groups.

[0052] After sorting the results in descending order based on the FDR value, and setting a threshold of 0.05, 21 enriched functional nodes were obtained, as shown in the table below:

[0053]

[0054]

[0055] To identify key genes in the aforementioned pathways, an ensemble decision-making approach was used to rank the importance of all genes enriched in the aforementioned functional nodes / pathways. The top three genes (CAMKK2, IKBKB, and MAP3K13) were selected for validation using a dual-luciferase reporter gene assay. As shown in the figure below, the results indicate that the top-ranked gene, CAMKK2, has a potential binding site with tRFVal-AAC-035.

[0056]

[0057] Tracing back to the source, CAMKK2 was found to be mainly enriched in functional nodes and pathways related to ferroptosis (AMPK signaling pathway, GAD-IMMUNE), autophagy (MAPK cascade, calcium binding, calcium-dependent protein kinase activity, calcium ion binding, calcium-mediated signaling, ATP binding), and insulin resistance (Adipocytokine signaling pathway). Specifically... Figure 5 As shown:

[0058] Example 5: tRFVal-AAC-035 targets and regulates the expression of CAMKK2, PI3K, and IKK. As mentioned above, tRFVal-AAC-035 has potential binding sites with the mRNAs of CAMKK2, PI3K, and IKK, and may regulate the expression of downstream target genes. The expression of CAMKK2, PI3K, and IKK was detected in cardiomyocytes treated with high glucose + PA and in diabetes-induced heart tissue. The results showed decreased expression of CAMKK2 and PI3K, and increased expression of IKK. Simultaneously, the expression of CAMKK2, PI3K, and IKK was detected by overexpression or silencing of tRFVal-AAC-035 in cardiomyocytes. Overexpression of tRFVal-AAC-035 promoted the expression of CAMKK2 and PI3K, and downregulated the expression of IKK; while silencing tRFVal-AAC-035 had the opposite effect, decreasing the expression of CAMKK2 and PI3K, and increasing the expression of IKK. See [link to relevant documentation]. Figure 6 .

[0059] Example 6: tRFVal-AAC-035 inhibits high glucose + PA-induced increased ferroptosis in cardiomyocytes

[0060] Primary cardiomyocytes treated with high glucose plus PA showed increased expression of ferroptosis-related proteins, including GPX4 and FTH1, indicating increased ferroptosis. However, overexpression of tRFVal-AAC-035 inhibited this effect, while silencing tRFVal-AAC-035 exacerbated the increased ferroptosis induced by high glucose plus PA treatment. (See...) Figure 7 .

Claims

1. The application of a reagent for quantitative detection of tRFVal-AAC-035 in the preparation of a diagnostic kit for diabetic cardiomyopathy, wherein tRFVal-AAC-035, as a marker for diagnosing diabetic cardiomyopathy, has the following structure: GTTTCCGTAGTGTAGTGGTCATCA. The kit includes a solvent or solute, the solvent being selected from organic solvents, inorganic solvents, buffer solutions, and water; the kit also includes a test instruction manual, reagent bottles, reagent packs, cotton swabs, droppers, and other additional devices; the application includes RNA extraction and detection of tRFVal-AAC-035, the detection being performed using fluorescence PCR quantification.

2. The application according to claim 1, wherein the reagents in the kit can test 1 person or multiple people, wherein multiple people can test 5 people, 10 people, 20 people, 50 people or 100 people.